RESPON TERAPI ANTIRETROVIRAL PADA PASIEN HIV/AIDS DI RSUP DR. SARDJITO YOGYAKARTA
The use of antiretroviral drugs (ARV) can suppress HIV viral replication, increasing the life expectancy of people with HIV/AIDS (PLWHA) and the quality of life of people living with HIV. Activity monitoring clinical response, immunological, and virulogis routinely required in patients with HIV / AI...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Theses and Dissertations NonPeerReviewed |
| Published: |
[Yogyakarta] : Universitas Gadjah Mada
2014
|
| Subjects: | |
| Online Access: | https://repository.ugm.ac.id/132238/ http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=72759 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The use of antiretroviral drugs (ARV) can suppress HIV viral replication,
increasing the life expectancy of people with HIV/AIDS (PLWHA) and the quality of
life of people living with HIV. Activity monitoring clinical response, immunological,
and virulogis routinely required in patients with HIV / AIDS to monitor the success
and failure of antiretroviral therapy. The study aimed to determine the response of
antiretroviral therapy based on clinical and immunological markers in patients with
HIV / AIDS in RSUP Dr. Sardjito.
This is a cross sectional descriptive research and the data are collected
retrospectively from the patient medical record. Descriptive statistic is used to
analysed the data. The data are taken from the patient who meet the criteria, which is
over 18 years old patient, own complete medical record, diagnosed early and/or
advanced stage, own CD4 data and weight a minimum two data. The response
therapy can be seen from immunological markers, which is changes in CD4 and
clinical markers such as changes in body weight.
Totality there are 63 HIV/AIDS patient which meet inclusion criteria. The result
of research indicate in first line ARV therapy regimen that combination of
zidovudin+lamivudin+nevirapine is used mostly exactly for 24 patients (38,10%).
CD4 count increase after ARV therapy in 6, 12, dan 24 months are occur on 27
patients (81,82%), 40 patients (83,33%), and 43 patients (82,69%). Increasing of
body weight in 6, 12, and 24 months after therapy ARV are 34 patients (72,34%), 33
patients (82,50%), and 36 patients (81,82%). Increasing of body weight not always
followed increasing of CD4 count after six months ARV therapy |
|---|